论文部分内容阅读
重组组织型纤维蛋白溶酶原激活剂(rt—PA)已广泛用于急性心肌梗塞(AMI)的治疗,有效率约71%,但据报道有0.4%～1.3%患者发生颅内出血(ICH)。因此,本文旨在确定这种血栓溶解疗法引起 ICH 的临床特征及有关的危险因素。病人与方法在1700例应用双链 rt-PA、duteplase 和肝素治疗的 AMI 病人中,作者收集9例发生 ICH 病人的详细病史,了解 AMI 前应用过的抗凝或抗血小板药物,体格检查和凝血
Recombinant tissue-type plasminogen activator (rt-PA) has been widely used in the treatment of acute myocardial infarction (AMI), the effective rate of about 71%, but it has been reported in 0.4% to 1.3% of patients with intracranial hemorrhage (ICH) . Therefore, this article aims to determine the clinical characteristics of thrombolytic therapy that cause ICH and related risk factors. PATIENTS AND METHODS In a sample of 1,700 AMI patients treated with double-stranded rt-PA, duteplase, and heparin, the authors collected a detailed medical history of 9 patients with ICH and studied anticoagulant or anti-platelet medications, physical examinations, and clotting used prior to AMI